KPTI

Karyopharm Therapeutics Inc. | Cotação de Ações

Última atualização08/08/2025, 16:06:03

PreçoUS$ 4,04

Variação (dia)US$ 0,07 (1.76%)▲

Min. 52 SemanasUS$ 3,51

Máx. 52 SemanasUS$ 16,95

Capitalização de mercado--

Endereço: 85 Wells Avenue, Newton, MA, 02459-3298

Telefone: 617 658 0600

Funcionários: 279

Karyopharm Therapeutics Inc.KPTI

US$ 4,04

+ 0,071,8%

08/08/2025 16:06:03

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 4,04

Valor de mercado--

AberturaUS$ 4,01

Preço máximoUS$ 4,07

Preço mínimoUS$ 3,83

VolumeUS$ 67 mil

Fechamento anteriorUS$ 3,97

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Ações relacionadas

MacroGenics, Inc.

MGNX ▼0.00% | US$ 3,00

Heron Therapeutics, Inc.

HRTX ▼0.00% | US$ 1,63

FibroGen, Inc.

FGEN ▼0.04% | US$ 0,53

TG Therapeutics, Inc.

TGTX ▲0.31% | US$ 29,86

Atara Biotherapeutics, Inc.

ATRA ▼0.52% | US$ 6,05

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.